AR031094A1 - Compuestos derivados de anilina, utiles como ligandos para el receptor de la tiroides, y las composiciones y combinaciones farmaceuticas que las contienen - Google Patents

Compuestos derivados de anilina, utiles como ligandos para el receptor de la tiroides, y las composiciones y combinaciones farmaceuticas que las contienen

Info

Publication number
AR031094A1
AR031094A1 ARP010100730A ARP010100730A AR031094A1 AR 031094 A1 AR031094 A1 AR 031094A1 AR P010100730 A ARP010100730 A AR P010100730A AR P010100730 A ARP010100730 A AR P010100730A AR 031094 A1 AR031094 A1 AR 031094A1
Authority
AR
Argentina
Prior art keywords
hydrogen
useful
compounds
alkyl
combinations containing
Prior art date
Application number
ARP010100730A
Other languages
English (en)
Inventor
Todd Jason Friends
Denis Ryono
Minsheng Zhang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR031094A1 publication Critical patent/AR031094A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/27—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se proporcionan compuestos derivados de anilina que son utiles como ligandos para los receptores de la tiroides, los cuales tienen la formula general (1) en la cual: X es oxígeno (-O-), azufre (-S-), carbonilo (-CO-), metileno (-CH2-), o -NH-; Y es -(CH2)n- donde n es un entero de 1 a 5, o -C=C- caracterizado porque puede ser cis o trans; R1 es halogeno, trifluorometilo, o alquilo C1-6 o cicloalquilo C3-7; R2 y R3 son los mismo o diferentes y son hidrogeno, halogeno, alquilo C1-4 o cicloalquilo C3-6, al menos uno de R2 y R3 son diferentes de hidrogeno; R4 es hidrogeno o alquilo inferior; R5 es hidrogeno o alquilo inferior; R6 es ácido carboxílico, o un éster del mismo, o un profármaco del mismo; R7 es hidrogeno o un grupo alcanoilo o un aroilo. Dichos compuestos son utiles para prevenir, inhibir o tratar un padecimiento asociado con la disfuncion del metabolismo, o que es dependiente de la expresion de un gen regulado por T3. Los ejemplos de tales padecimientos asociados con la disfuncion del metabolismo o que son dependientes de la expresion de un gen regulado T3 incluyen, la obesidad, hipercolesterolemia, arteroesclerosis, arritmias cardiacas, depresion, osteoporosis, hipotiroidismo, gota, cáncer de la tiroides así también como glaucoma, insuficiencia cardiaca congestiva y alteraciones de la piel. También se describen las composiciones y combinaciones farmacéuticas que contienen dichos compuestos.
ARP010100730A 2000-02-17 2001-02-16 Compuestos derivados de anilina, utiles como ligandos para el receptor de la tiroides, y las composiciones y combinaciones farmaceuticas que las contienen AR031094A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18322300P 2000-02-17 2000-02-17

Publications (1)

Publication Number Publication Date
AR031094A1 true AR031094A1 (es) 2003-09-10

Family

ID=22671959

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010100730A AR031094A1 (es) 2000-02-17 2001-02-16 Compuestos derivados de anilina, utiles como ligandos para el receptor de la tiroides, y las composiciones y combinaciones farmaceuticas que las contienen

Country Status (30)

Country Link
US (2) US6800605B1 (es)
EP (1) EP1257526B1 (es)
JP (1) JP4629294B2 (es)
KR (1) KR100740383B1 (es)
CN (1) CN1216857C (es)
AR (1) AR031094A1 (es)
AT (1) ATE295348T1 (es)
AU (2) AU3092901A (es)
BR (1) BR0108134A (es)
CA (1) CA2400486C (es)
CO (1) CO5271672A1 (es)
CZ (1) CZ20022771A3 (es)
DE (1) DE60110753T2 (es)
DK (1) DK1257526T3 (es)
EG (1) EG25009A (es)
ES (1) ES2242723T3 (es)
HK (1) HK1047925B (es)
HU (1) HUP0301777A3 (es)
IL (2) IL150449A0 (es)
MX (1) MXPA02007929A (es)
MY (1) MY124534A (es)
NO (1) NO329639B1 (es)
NZ (1) NZ520023A (es)
PE (1) PE20020767A1 (es)
PL (1) PL201790B1 (es)
PT (1) PT1257526E (es)
RU (1) RU2260586C2 (es)
UY (1) UY26581A1 (es)
WO (1) WO2001060784A1 (es)
ZA (1) ZA200206072B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664291B2 (en) 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
DE10131462A1 (de) * 2001-06-29 2003-01-09 Bayer Ag Phenol-Derivate
US6806381B2 (en) 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
EP1448512A1 (en) * 2001-11-17 2004-08-25 NeuroSearch A/S Prodrugs of antidepressants and their use for treating depressions
GB0208384D0 (en) * 2002-04-11 2002-05-22 Karobio Ab Novel compounds
WO2004066929A2 (en) * 2003-01-24 2004-08-12 Bristol-Myers Squibb Company Cycloalkyl containing anilide ligands for the thyroid receptor
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
CA2535614C (en) * 2003-08-14 2009-12-22 Array Biopharma Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
KR20060109926A (ko) 2003-11-19 2006-10-23 메타베이시스 테라퓨틱스, 인크. 새로운 인-함유 갑상선 호르몬 모방약들
GB0406378D0 (en) * 2004-03-22 2004-04-21 Karobio Ab Novel pharmaceutical compositions
MX2007014502A (es) 2005-05-26 2008-02-07 Metabasis Therapeutics Inc Tiromimeticos para el tratamiento de enfermedades del higado graso.
GB0606201D0 (en) * 2006-03-28 2006-05-10 Karobio Ab Improved crytalline material
GB0606212D0 (en) * 2006-03-28 2006-05-10 Karobio Ab Pharmaceutical compositions
US20070238770A1 (en) * 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
GB0724478D0 (en) * 2007-12-14 2008-01-30 Karobio Ab Pharmaceutical compositions
US20090197947A1 (en) * 2008-02-01 2009-08-06 The Research Foundation Of State University Of New York Medicaments and methods for lowering plasma lipid levels and screening drugs
US8922530B2 (en) * 2010-01-06 2014-12-30 Apple Inc. Communicating stylus
EP2609910A1 (en) 2011-12-30 2013-07-03 Deva Holding Anonim Sirketi Formulations of eprotirome
DK2695611T3 (en) * 2012-08-06 2015-01-05 Wolff August Gmbh & Co Kg Arzneimittel Dr Eprotirome for use in the prevention and / or treatment of hair disorders and their compositions
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
KR102331596B1 (ko) * 2016-05-18 2021-11-25 오레곤 헬스 앤드 사이언스 유니버시티 소베티롬의 유도체
JP2020500199A (ja) 2016-11-21 2020-01-09 バイキング・セラピューティクス・インコーポレイテッド グリコーゲン蓄積症の治療方法
EP3634426A4 (en) 2017-06-05 2021-04-07 Viking Therapeutics, Inc. COMPOSITIONS FOR THE TREATMENT OF FIBROSIS
US11787828B2 (en) 2018-03-22 2023-10-17 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
US11827596B2 (en) 2018-12-12 2023-11-28 Autobahn Therapeutics, Inc. Thyromimetics
US20220162161A1 (en) 2019-02-21 2022-05-26 Nanjing Ruijie Pharma Co., Ltd. Novel compounds and their uses as thyroid hormone receptor agonists
EP3931180A1 (en) 2019-03-01 2022-01-05 Autobahn Therapeutics, Inc. Novel thyromimetics
JP2023528637A (ja) 2020-06-02 2023-07-05 成都康弘▲葯▼▲業▼集▲團▼股▲フン▼有限公司 新規甲状腺ホルモンβ受容体アゴニスト
WO2023177667A1 (en) * 2022-03-16 2023-09-21 Brii Biosciences, Inc. Thyroid hormone receptor agonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1078582B (de) * 1958-10-29 1960-03-31 Hoechst Ag Verfahren zur Herstellung substituierter Thyropropionsaeuren
JPS6061747A (ja) * 1983-09-16 1985-04-09 Konishiroku Photo Ind Co Ltd 熱現像感光材料
DK0580550T3 (da) 1992-07-21 1998-02-02 Ciba Geigy Ag Oxamidsyrederivater som hypercholesterolæmiske midler
GB9713739D0 (en) * 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
ATE289586T1 (de) 1999-03-01 2005-03-15 Pfizer Prod Inc Oxamsäuren mit einer cyanogruppe als liganden für den thyroidrezeptor
CN1345303A (zh) 1999-03-01 2002-04-17 辉瑞产品公司 用作甲状腺受体配体的草氨酸及衍生物
CO5160290A1 (es) 1999-03-29 2002-05-30 Novartis Ag Derivados de acido fenoxifeniloxamico sustituido .
ES2240017T3 (es) 1999-09-30 2005-10-16 Pfizer Products Inc. Derivados de 6-azauracilo como ligandos de receptores tiroideos.
US6664291B2 (en) 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
ATE382602T1 (de) * 2000-03-31 2008-01-15 Pfizer Prod Inc Malonsäureamide sowie deren derivate als thyroidrezeptor liganden
AU4884701A (en) * 2000-05-12 2001-11-20 Kissei Pharmaceutical Co. Ltd. Malonanilic acid derivatives, medicinal compositions containing the same and usethereof
WO2002094319A1 (en) * 2001-05-18 2002-11-28 Kissei Pharmaceutical Co., Ltd. Preventive or recurrence-suppressive agents for liver cancer
TW200504021A (en) * 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor

Also Published As

Publication number Publication date
CA2400486C (en) 2011-01-11
RU2002123349A (ru) 2004-01-10
HK1047925B (zh) 2005-11-11
NZ520023A (en) 2004-05-28
US7109164B2 (en) 2006-09-19
DE60110753D1 (de) 2005-06-16
BR0108134A (pt) 2003-09-30
RU2260586C2 (ru) 2005-09-20
DE60110753T2 (de) 2006-02-23
ZA200206072B (en) 2004-02-11
JP4629294B2 (ja) 2011-02-09
NO329639B1 (no) 2010-11-22
ES2242723T3 (es) 2005-11-16
CO5271672A1 (es) 2003-04-30
MXPA02007929A (es) 2003-02-10
CZ20022771A3 (cs) 2003-09-17
ATE295348T1 (de) 2005-05-15
CN1216857C (zh) 2005-08-31
MY124534A (en) 2006-06-30
WO2001060784A1 (en) 2001-08-23
US6800605B1 (en) 2004-10-05
US20050032890A1 (en) 2005-02-10
CN1418185A (zh) 2003-05-14
PL201790B1 (pl) 2009-05-29
IL150449A (en) 2008-03-20
EP1257526B1 (en) 2005-05-11
HUP0301777A3 (en) 2010-09-28
KR20020075799A (ko) 2002-10-05
NO20023895D0 (no) 2002-08-16
PT1257526E (pt) 2005-09-30
CA2400486A1 (en) 2001-08-23
AU3092901A (en) 2001-08-27
HUP0301777A2 (hu) 2003-09-29
PL366149A1 (en) 2005-01-24
NO20023895L (no) 2002-10-16
IL150449A0 (en) 2002-12-01
JP2004500382A (ja) 2004-01-08
EG25009A (en) 2011-05-16
HK1047925A1 (en) 2003-03-14
UY26581A1 (es) 2001-09-28
AU2001230929B2 (en) 2004-09-23
EP1257526A1 (en) 2002-11-20
PE20020767A1 (es) 2002-08-17
DK1257526T3 (da) 2005-09-12
KR100740383B1 (ko) 2007-07-16

Similar Documents

Publication Publication Date Title
AR031094A1 (es) Compuestos derivados de anilina, utiles como ligandos para el receptor de la tiroides, y las composiciones y combinaciones farmaceuticas que las contienen
ES2144412T3 (es) Derivados de bencimidazoles como antagonistas de 5-ht1a y 5ht2.
ATE370117T1 (de) Benzamidliganden für den thyroid-rezeptor
AR061644A1 (es) Derivados de benzofurano
PT1000008E (pt) Novos ligandos do receptor da tiroide e processo
TW200602339A (en) Substituted diaza-spiro-[5.5]-undecane derivatives and their use as neurokinin antagonists
GT200800058A (es) Diarilurea para el tratamiento de hipertensión pulmonar
PE20061013A1 (es) Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias
PE20011264A1 (es) Analogos de tetrahidroisoquinolina utiles como secretagogos de la hormona del crecimiento
MX2021003585A (es) Composicion para el cuidado personal que comprende compuesto organico solido insoluble en agua.
ATE340795T1 (de) Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten
PE20000127A1 (es) Derivado de bencenosulfonamida
PE20060557A1 (es) Derivados de n-(1h-indolil)-1h-indol-2-carboxamidas como antagonistas de los receptores trpv1
AR074352A1 (es) Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatitis atopica.
FR3081865B1 (fr) Compositions a base de 1,1,2-trifluoroethylene et de dioxyde de carbone
PE83999A1 (es) Azetidinas
BR0206495A (pt) Tratamento de distúrbios de cns empregando antagonistas de oxidase de d-aminoácido e oxidase de d-aspartato
DE602006014531D1 (de) Substituierte oxadiazaspiro-ä5.5ü-undecanonderivate und ihre verwendung als neurokininantagonisten
DE59710955D1 (de) Dispersionen von optischen Aufhellern
GT200000197A (es) 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6- morfolin-4-il-4-o tolil-piridin-3-il)-isobutiramida.
PE20040682A1 (es) Derivados de ciclobutano como antagonistas de nk1
AR042909A1 (es) Ligandos de anilida substituidos por el receptor de tiroides
BRPI0509084A (pt) composição aquosa, método de tratamento, e, lata pulverizadora
MX2007005566A (es) Sulfamidas como antagonistas de receptor de endotelina para el tratamiento de enfermedades cardiovasculares.
AR012260A1 (es) Composicion que comprende un polimero que contiene halogeno y una composicion estabilizadora que comprende un mercaptano bloqueado y unsinergista

Legal Events

Date Code Title Description
FG Grant, registration